Crescent Biopharma Inc
CBIO
NASDAQ
Biotechnology
$17.14
USD
+0.51 (+3.07%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $617.70M
Volume 229.9K
Revenue
$11.88M
TTM
-86.2%
YoY
Gross Margin
100%
TTM
+4.1%
YoY
Net Income
$-165.12M
TTM
-2523.9%
YoY
Operating Cash Flow
$-72.68M
TTM
-1285.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 10.8 | 1.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 10.8 | 1.0 | 0.0 |
Selling, General & Administrative | 8.9 | 5.5 | 7.3 | 7.9 | 8.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | -1.8 |
Total Operating Expenses | 21.0 | 25.9 | 102.3 | 25.8 | 26.4 |
Operating Income | -21.0 | -25.9 | -91.5 | -24.7 | -26.4 |
EBITDA | -21.0 | -25.9 | -91.4 | -24.7 | -26.3 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -0.8 | 1.3 | 1.1 | 1.4 | 1.5 |
Income Before Income Taxes | -21.8 | -24.6 | -90.4 | -23.3 | -24.8 |
Income Taxes | 0.0 | 0.0 | 2.0 | 0.0 | 0.0 |
Net Income | -21.8 | -24.6 | -92.4 | -23.3 | -24.8 |
Consolidated Net Income / Loss | -21.8 | -24.6 | -92.4 | -23.3 | -24.8 |
Net Income Attributable to Common Shareholders | -19.0 | -20.9 | -81.1 | -21.3 | -22.7 |
Basic EPS | -$4.93 | -$1.27 | -$3.96 | -$0.70 | -$0.74 |
Diluted EPS | -$4.93 | -$1.27 | -$3.96 | -$0.70 | -$0.74 |
Basic Shares Outstanding | 3.9M | 16.5M | 20.5M | 30.4M | 30.5M |
Diluted Shares Outstanding | 3.9M | 16.5M | 20.5M | 30.4M | 30.5M |